A biomarker trial of VS-041
Latest Information Update: 11 Jun 2025
At a glance
- Drugs VS 041 (Primary)
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 11 Jun 2025 New trial record
- 04 Jun 2025 According to a Vasa Therapeutics media release, the company plan to advance development of VS-041 and test its effects on clinical and prognostic biomarkers of HFpEF, including endotrophin, in the target patient population later this year.